Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Scholar Rock Holding Corp (SRRK) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Scholar Rock Holding Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1727196.
Total stock buying since 2018: $66,114,914.
Total stock sales since 2018: $154,796,264.
Total stock option exercises since 2018: $7,832,219.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 462,672 | $16,796,826 | 200,085 | $2,616,133 |
| 2024 | 0 | $0 | 3,628,436 | $129,797,769 | 393,427 | $4,554,967 |
| 2023 | 6,611,050 | $47,137,914 | 76,772 | $1,145,554 | 37,373 | $181,632 |
| 2022 | 1,428,228 | $7,677,012 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 156,676 | $7,056,115 | 41,020 | $479,487 |
| 2018 | 807,142 | $11,299,988 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 2,178 | $67,879 | 0 | $0 |
| 2025-07 | 0 | $0 | 35,202 | $1,274,589 | 0 | $0 |
| 2025-06 | 0 | $0 | 51,779 | $1,679,724 | 20,316 | $439,231 |
| 2025-05 | 0 | $0 | 33,075 | $982,239 | 0 | $0 |
| 2025-03 | 0 | $0 | 163,362 | $5,729,612 | 131,461 | $1,715,175 |
| 2025-02 | 0 | $0 | 109,864 | $4,092,217 | 48,308 | $461,727 |
| 2025-01 | 0 | $0 | 67,212 | $2,970,566 | 0 | $0 |
| 2024-12 | 0 | $0 | 1,600,000 | $66,640,000 | 0 | $0 |
| 2024-11 | 0 | $0 | 420,058 | $16,485,936 | 10,625 | $91,267 |
| 2024-10 | 0 | $0 | 1,558,515 | $45,938,835 | 382,802 | $4,463,700 |
| 2024-09 | 0 | $0 | 1,936 | $16,610 | 0 | $0 |
| 2024-08 | 0 | $0 | 1,451 | $13,537 | 0 | $0 |
| 2024-06 | 0 | $0 | 4,695 | $42,184 | 0 | $0 |
| 2024-02 | 0 | $0 | 26,110 | $411,047 | 0 | $0 |
| 2024-01 | 0 | $0 | 15,671 | $249,620 | 0 | $0 |
| 2023-12 | 0 | $0 | 37,373 | $675,568 | 37,373 | $181,632 |
| 2023-11 | 0 | $0 | 35,007 | $438,042 | 0 | $0 |
| 2023-10 | 6,579,493 | $46,935,066 | 0 | $0 | 0 | $0 |
| 2023-09 | 0 | $0 | 1,945 | $12,331 | 0 | $0 |
| 2023-08 | 0 | $0 | 1,353 | $9,240 | 0 | $0 |
| 2023-04 | 31,557 | $202,848 | 0 | $0 | 0 | $0 |
| 2023-01 | 0 | $0 | 1,094 | $10,373 | 0 | $0 |
| 2022-10 | 230,236 | $1,806,852 | 0 | $0 | 0 | $0 |
| 2022-06 | 1,197,992 | $5,870,160 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | Parlavecchio Caryn (CHRO) | Sale | 2,178 | 31.17 | 67,879 |
| 2025-07-16 | Flier Jeffrey S. | Sale | 11,136 | 40.02 | 445,684 |
| 2025-07-08 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 24,066 | 34.44 | 828,905 |
| 2025-06-23 | Flier Jeffrey S. | Sale | 31,452 | 32.70 | 1,028,511 |
| 2025-06-23 | Flier Jeffrey S. | Option Ex | 20,316 | 21.62 | 439,231 |
| 2025-06-16 | Peng Katie | Sale | 3,031 | 32.24 | 97,725 |
| 2025-06-16 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 3,668 | 32.00 | 117,379 |
| 2025-06-16 | Parlavecchio Caryn (CHRO) | Sale | 6,186 | 32.00 | 197,958 |
| 2025-06-16 | Ho Junlin (GENERAL COUNSEL) | Sale | 7,442 | 32.00 | 238,151 |
| 2025-05-29 | Reed Joshua | Sale | 5,400 | 29.86 | 161,260 |
| 2025-05-29 | Flier Jeffrey S. | Sale | 6,075 | 29.53 | 179,412 |
| 2025-05-29 | Brudnick Richard | Sale | 6,075 | 29.82 | 181,138 |
| 2025-05-29 | Burow Kristina | Sale | 5,400 | 29.54 | 159,505 |
| 2025-05-29 | Vaishnaw Akshay (President of R&D) | Sale | 6,750 | 29.82 | 201,271 |
| 2025-05-29 | Gilman Michael | Sale | 3,375 | 29.53 | 99,653 |
| 2025-03-24 | Sacco Tracey (Chief Commercial Officer) | Sale | 6,500 | 33.30 | 216,437 |
| 2025-03-24 | Sacco Tracey (Chief Commercial Officer) | Option Ex | 5,000 | 10.00 | 50,000 |
| 2025-03-24 | Moore Erin (Interim PFO and PAO) | Sale | 13,564 | 33.12 | 449,239 |
| 2025-03-24 | Moore Erin (Interim PFO and PAO) | Option Ex | 13,564 | 18.69 | 253,511 |
| 2025-03-17 | Peng Katie | Sale | 1,006 | 34.42 | 34,626 |
| 2025-03-10 | Myles Edward H (COO & CFO) | Sale | 142,292 | 35.34 | 5,029,310 |
| 2025-03-10 | Myles Edward H (COO & CFO) | Option Ex | 112,897 | 12.50 | 1,411,664 |
| 2025-02-19 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 68,510 | 37.50 | 2,569,193 |
| 2025-02-19 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Option Ex | 48,308 | 9.56 | 461,727 |
| 2025-02-18 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 4,135 | 36.83 | 152,287 |
| 2025-02-18 | Parlavecchio Caryn (CHRO) | Sale | 5,296 | 36.83 | 195,046 |
| 2025-02-18 | Ho Junlin (GENERAL COUNSEL) | Sale | 5,742 | 36.83 | 211,472 |
| 2025-02-18 | Backstrom Jay T. (CHIEF EXECUTIVE OFFICER) | Sale | 18,372 | 36.83 | 676,622 |
| 2025-02-18 | Myles Edward H (COO & CFO) | Sale | 7,809 | 36.83 | 287,597 |
| 2025-01-16 | Sacco Tracey (Chief Commercial Officer) | Sale | 3,890 | 44.20 | 171,926 |
| 2025-01-16 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 7,347 | 44.20 | 324,715 |
| 2025-01-16 | Parlavecchio Caryn (CHRO) | Sale | 6,434 | 44.20 | 284,363 |
| 2025-01-16 | Ho Junlin (GENERAL COUNSEL) | Sale | 9,039 | 44.20 | 399,496 |
| 2025-01-16 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Sale | 5,655 | 44.20 | 249,934 |
| 2025-01-16 | Backstrom Jay T. (CHIEF EXECUTIVE OFFICER) | Sale | 22,308 | 44.20 | 985,946 |
| 2025-01-16 | Myles Edward H (COO & CFO) | Sale | 12,539 | 44.20 | 554,186 |
| 2024-12-10 | Debbane Raymond | Sale | 1,600,000 | 41.65 | 66,640,000 |
| 2024-11-25 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Sale | 6,375 | 39.49 | 251,723 |
| 2024-11-25 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Option Ex | 6,375 | 8.59 | 54,761 |
| 2024-11-25 | Debbane Raymond | Sale | 409,433 | 39.34 | 16,106,684 |
| 2024-11-22 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Sale | 2,145 | 30.01 | 64,371 |
| 2024-11-22 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Option Ex | 2,145 | 8.59 | 18,425 |
| 2024-11-11 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Sale | 2,105 | 30.00 | 63,158 |
| 2024-11-11 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Option Ex | 2,105 | 8.59 | 18,081 |
| 2024-10-08 | Myles Edward H (COO & CFO) | Sale | 37,187 | 34.90 | 1,297,677 |
| 2024-10-08 | Myles Edward H (COO & CFO) | Option Ex | 37,187 | 10.00 | 371,870 |
| 2024-10-07 | Sacco Tracey (CHIEF COMMERCIAL OFFICER) | Sale | 30,000 | 25.91 | 777,150 |
| 2024-10-07 | Sacco Tracey (CHIEF COMMERCIAL OFFICER) | Option Ex | 30,000 | 10.00 | 300,000 |
| 2024-10-07 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Sale | 109,375 | 27.29 | 2,984,953 |
| 2024-10-07 | Marantz Jing L. (CHIEF MEDICAL OFFICER) | Option Ex | 109,375 | 8.59 | 939,531 |
| 2024-10-07 | Myles Edward H (COO & CFO) | Sale | 206,240 | 27.19 | 5,607,665 |
| 2024-10-07 | Myles Edward H (COO & CFO) | Option Ex | 206,240 | 13.83 | 2,852,299 |
| 2024-10-07 | Akkaraju Srinivas | Sale | 1,175,713 | 30.00 | 35,271,390 |
| 2024-09-16 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 1,936 | 8.58 | 16,610 |
| 2024-08-16 | Parlavecchio Caryn (CHRO) | Sale | 1,451 | 9.33 | 13,537 |
| 2024-06-17 | Ho Junlin (GENERAL COUNSEL) | Sale | 4,695 | 8.98 | 42,184 |
| 2024-02-16 | Qatanani Mo (CHIEF SCIENTIFIC OFFICER) | Sale | 2,512 | 15.74 | 39,546 |
| 2024-02-16 | Parlavecchio Caryn (CHRO) | Sale | 3,751 | 15.74 | 59,051 |
| 2024-02-16 | Ho Junlin (GENERAL COUNSEL) | Sale | 3,489 | 15.74 | 54,927 |
| 2024-02-16 | Backstrom Jay T. (CHIEF EXECUTIVE OFFICER) | Sale | 11,614 | 15.74 | 182,839 |
| 2024-02-16 | Myles Edward H (COO & CFO) | Sale | 4,744 | 15.74 | 74,684 |
| 2024-01-16 | Qatanani Mo (SVP AND HEAD OF RESEARCH) | Sale | 2,002 | 15.93 | 31,889 |
| 2024-01-16 | Parlavecchio Caryn (CHRO) | Sale | 2,849 | 15.93 | 45,381 |
| 2024-01-16 | Ho Junlin (GENERAL COUNSEL) | Sale | 4,186 | 15.93 | 66,678 |
| 2024-01-16 | Myles Edward H (COO & CFO) | Sale | 6,634 | 15.93 | 105,672 |
| 2023-12-29 | Myles Edward H (COO & CFO) | Sale | 12,459 | 19.16 | 238,751 |
| 2023-12-29 | Myles Edward H (COO & CFO) | Option Ex | 12,459 | 4.86 | 60,550 |
| 2023-12-07 | Myles Edward H (COO & CFO) | Sale | 24,914 | 17.53 | 436,817 |
| 2023-12-07 | Myles Edward H (COO & CFO) | Option Ex | 24,914 | 4.86 | 121,082 |
| 2023-11-02 | Myles Edward H (COO & CFO) | Sale | 35,007 | 12.51 | 438,042 |
| 2023-10-16 | Samsara Biocapital, L.p. (10% Owner) | Buy | 2,189,781 | 6.85 | 14,999,999 |
| 2023-10-16 | Akkaraju Srinivas (Director) | Buy | 2,189,781 | 6.85 | 14,999,999 |
| 2023-10-12 | Invus Public Equities Advisors, Llc | Buy | 2,199,931 | 7.70 | 16,935,068 |
| 2023-09-18 | Qatanani Mo (SVP AND HEAD OF RESEARCH) | Sale | 1,945 | 6.34 | 12,331 |
| 2023-08-16 | Parlavecchio Caryn (CHRO) | Sale | 1,353 | 6.83 | 9,240 |
| 2023-04-28 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 31,557 | 6.43 | 202,848 |
| 2023-01-09 | Invus Public Equities Advisors, Llc (10% Owner) | Sale | 1,094 | 9.48 | 10,373 |
| 2022-10-25 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 130,265 | 8.04 | 1,047,330 |
| 2022-10-04 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 66,000 | 7.89 | 520,740 |
| 2022-10-03 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 33,971 | 7.03 | 238,782 |
| 2022-06-22 | Nashat Amir (Director) | Buy | 1,197,992 | 4.90 | 5,870,160 |
| 2021-11-15 | Myles Edward H (Chief Financial Officer) | Sale | 4,879 | 35.05 | 171,004 |
| 2021-11-12 | Myles Edward H (Chief Financial Officer) | Sale | 49,848 | 35.12 | 1,750,462 |
| 2021-11-11 | Myles Edward H (Chief Financial Officer) | Sale | 23,574 | 35.20 | 829,851 |
| 2021-10-01 | Flier Jeffrey S. | Sale | 6,000 | 30.89 | 185,328 |
| 2021-09-20 | Flier Jeffrey S. | Sale | 500 | 34.09 | 17,045 |
| 2021-07-26 | Flier Jeffrey S. | Sale | 6,000 | 31.66 | 189,966 |
| 2021-03-15 | Gilman Michael | Sale | 4,696 | 65.59 | 307,996 |
| 2021-02-08 | Gilman Michael | Sale | 1,804 | 65.06 | 117,361 |
| 2021-01-27 | Carven Gregory John (Head of Research) | Sale | 19,100 | 56.79 | 1,084,727 |
| 2021-01-27 | Carven Gregory John (Head of Research) | Option Ex | 6,619 | 15.11 | 100,013 |
| 2021-01-26 | Carven Gregory John (Head of Research) | Sale | 36,774 | 59.71 | 2,195,922 |
| 2021-01-26 | Carven Gregory John (Head of Research) | Option Ex | 30,900 | 11.63 | 359,274 |
| 2021-01-26 | Gilman Michael | Sale | 3,501 | 58.97 | 206,453 |
| 2021-01-26 | Gilman Michael | Option Ex | 3,501 | 5.77 | 20,200 |
| 2018-05-29 | Nashat Amir (Director) | Buy | 142,857 | 14.00 | 1,999,998 |
| 2018-05-29 | Polaris Venture Partners Founders' Fund Vi, L.p. (10% Owner) | Buy | 142,857 | 14.00 | 1,999,998 |
| 2018-05-29 | Minne Pascal (10% Owner) | Buy | 450,000 | 14.00 | 6,300,000 |
| 2018-05-29 | Springer Timothy A (Director) | Buy | 71,428 | 14.00 | 999,992 |
Insider trading activities including stock purchases, stock sales, and option exercises of SRRK listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Scholar Rock Holding Corp (symbol SRRK, CIK number 1727196) see the Securities and Exchange Commission (SEC) website.